Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours

MT Newswires Live2025-03-29

Bluebird bio (BLUE) received an unsolicited, nonbinding buyout proposal from Ayrmid for

an upfront cash payment of $4.50 a share and a one-time contingent value right of $6.84 a share, payable on reaching a net sales milestone.

Bluebird had agreed to be acquired by funds managed by Carlyle (CG) and SK Capital Partners for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.

Ayrmid didn't submit any proposal as part of the earlier review of alternatives, bluebird bio said Friday in a statement.

Bluebird bio said it "remains subject to the terms of the merger agreement" with Carlyle and SK Capital, and the board "has not changed its recommendation in support of the merger."

The board is reviewing the Ayrmid offer, which is "subject to certain conditions and further negotiations between the parties, including confirmatory diligence," blubird bio said.

The shares of bluebird bio jumped 9.1% in recent after-hours trading.

Price: 4.45, Change: +0.37, Percent Change: +9.07

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2523633753?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-29 04:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523633753","market":"fut","top_or_hot":-1,"title":"Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours","media":"MT Newswires Live","content":"<html><body><p> Bluebird bio (BLUE) received an unsolicited, nonbinding buyout proposal from Ayrmid for</p><p>an upfront cash payment of $4.50 a share and a one-time contingent value right of $6.84 a share, payable on reaching a net sales milestone.</p><p>Bluebird had agreed to be acquired by funds managed by Carlyle (CG) and SK Capital Partners for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.</p><p>Ayrmid didn't submit any proposal as part of the earlier review of alternatives, bluebird bio said Friday in a statement.</p><p>Bluebird bio said it \"remains subject to the terms of the merger agreement\" with Carlyle and SK Capital, and the board \"has not changed its recommendation in support of the merger.\"</p><p>The board is reviewing the Ayrmid offer, which is \"subject to certain conditions and further negotiations between the parties, including confirmatory diligence,\" blubird bio said.</p><p>The shares of bluebird bio jumped 9.1% in recent after-hours trading.</p><p>Price: 4.45, Change: +0.37, Percent Change: +9.07</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-29 04:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Bluebird bio (BLUE) received an unsolicited, nonbinding buyout proposal from Ayrmid for</p><p>an upfront cash payment of $4.50 a share and a one-time contingent value right of $6.84 a share, payable on reaching a net sales milestone.</p><p>Bluebird had agreed to be acquired by funds managed by Carlyle (CG) and SK Capital Partners for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.</p><p>Ayrmid didn't submit any proposal as part of the earlier review of alternatives, bluebird bio said Friday in a statement.</p><p>Bluebird bio said it \"remains subject to the terms of the merger agreement\" with Carlyle and SK Capital, and the board \"has not changed its recommendation in support of the merger.\"</p><p>The board is reviewing the Ayrmid offer, which is \"subject to certain conditions and further negotiations between the parties, including confirmatory diligence,\" blubird bio said.</p><p>The shares of bluebird bio jumped 9.1% in recent after-hours trading.</p><p>Price: 4.45, Change: +0.37, Percent Change: +9.07</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2523633753","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523633753","pubTimestamp":1743195005,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bluebird bio  received an unsolicited, nonbinding buyout proposal from Ayrmid foran upfront cash payment of $4.50 a share and a one-time contingent value right of $6.84 a share, payable on reaching a net sales milestone.Bluebird had agreed to be acquired by funds managed by Carlyle  and SK Capital Partners for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.Ayrmid didn't submit any proposal as part of the earlier review of alternatives, bluebird bio said Friday in a statement.Bluebird bio said it \"remains subject to the terms of the merger agreement\" with Carlyle and SK Capital, and the board \"has not changed its recommendation in support of the merger.\"The board is reviewing the Ayrmid offer, which is \"subject to certain conditions and further negotiations between the parties, including confirmatory diligence,\" blubird bio said.The shares of bluebird bio jumped 9.1% in recent after-hours trading.Price: 4.45, Change","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4578":"CAR-T","BK4139":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4135":"资产管理与托管银行","CG":"凯雷","BK4556":"基因编辑"},"translate_title":"Bluebird Bio收到Ayrmid的竞争对手收购提案；盘后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLUE":0.9,"CG":1},"content_text":"Bluebird bio (BLUE) received an unsolicited, nonbinding buyout proposal from Ayrmid foran upfront cash payment of $4.50 a share and a one-time contingent value right of $6.84 a share, payable on reaching a net sales milestone.Bluebird had agreed to be acquired by funds managed by Carlyle (CG) and SK Capital Partners for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.Ayrmid didn't submit any proposal as part of the earlier review of alternatives, bluebird bio said Friday in a statement.Bluebird bio said it \"remains subject to the terms of the merger agreement\" with Carlyle and SK Capital, and the board \"has not changed its recommendation in support of the merger.\"The board is reviewing the Ayrmid offer, which is \"subject to certain conditions and further negotiations between the parties, including confirmatory diligence,\" blubird bio said.The shares of bluebird bio jumped 9.1% in recent after-hours trading.Price: 4.45, Change: +0.37, Percent Change: +9.07","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2523633753","isCrawlerRequest":true}